Coronavirus
Moderna Announces Phase 3 of its COVID-19 Vaccine is 94.5% Effective
In another promising medical development, the biotechnology company Moderna has announced its COVID-19 vaccine could be up to 94.5% effective.
The news comes a week after Pfizer announced its vaccine could be up to 90% effective based on a similar, early analysis from its Phase 3 trial.
In a release Monday, Moderna said its Phase 3 trial “met statistical criteria with a vaccine efficacy of 94.5%,” according to an early analysis of the data that included 95 participants with confirmed cases of COVID-19.
However, vaccine specialists caution that these numbers are not set in stone — both estimates could increase or decrease as the respective trials continue, and the vaccines may ultimately prove to work better in some groups than in others.
